WO2025118737A1 - Nicotine replacement liquid preparation, and preparation method therefor and use thereof - Google Patents

Abstract

The present application relates to the technical field of electronic atomization, and specifically relates to a nicotine replacement liquid preparation, and a preparation method therefor and the use thereof. In the nicotine replacement liquid preparation provided in the present application, the raw material components of the nicotine replacement liquid preparation comprise an additive capable of simulating the throat-hit sensation of nicotine, an additive capable of simulating the head-rush sensation of nicotine, and an atomization solvent. The additive capable of simulating the throat-hit sensation of nicotine is selected from at least one of piperine and 6-methylnicotine; and the additive capable of simulating the head-rush sensation of nicotine is selected from at least one of cytisine, magnolol and 6-methylnicotine. The nicotine replacement liquid preparation of the present application simulates the head-rush sensation and throat-hit sensation brought about by nicotine, enhances the head-rush sensation and throat-hit sensation of a nicotine-free atomization preparation, and improves the sense of satisfaction of a user, thereby achieving the aim of relieving addiction physiologically. Moreover, the toxicity and addictiveness of the nicotine replacement liquid preparation are both much lower than nicotine, such that damages to health can be reduced.

Description

A nicotine replacement liquid preparation and its preparation method and application

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to the Chinese patent application filed with the China Patent Office on December 8, 2023, with application number 202311688629.5 and invention name “A nicotine replacement liquid preparation, preparation method and application thereof”, the entire contents of which are incorporated herein by reference.

Technical Field

The present application relates to the field of electronic atomization technology, and in particular to a nicotine replacement liquid preparation and a preparation method and application thereof.

Background Art

The electronic nicotine atomizer is a tobacco substitute product that does not deliver nicotine through tobacco smoke. Its working principle is to drive the atomizer through battery power, heat the electronic cigarette oil in the atomizer tank, and allow consumers to inhale aerosols containing or not containing nicotine, thereby producing the effect of smoking traditional tobacco products and achieving "smoking". At present, electronic atomizer preparations generally contain propylene glycol, glycerol, edible flavors and nicotine, which are mixed in a certain proportion. Propylene glycol, glycerol and edible flavors are all permitted food additives. Compared with traditional cigarettes, electronic nicotine atomizers do not require combustion, and the atomization process will not bring about tar, polycyclic aromatic hydrocarbons, carbon monoxide and other harmful substances produced by high-temperature combustion. At the same time, it will hardly bring the impact of second-hand smoke. It is a potential nicotine substitute that can achieve a certain smoking cessation effect.

Electronic nicotine atomizers can be used as a means of addiction relief. On the one hand, nicotine is added, because nicotine is addictive and is the main substance that causes addiction, which can relieve smokers' addiction physiologically. On the other hand, the smoking behavior of electronic nicotine atomizers is similar to that of cigarettes. Puffing out smoke can relieve smokers' addiction psychologically, but nicotine is highly toxic and addictive, and long-term inhalation will affect human health. At present, the market supervision of nicotine is constantly strengthening, and countries have begun to limit the nicotine content in electronic cigarettes to no more than 20mg/g; based on the health and safety of the public, many countries have also promoted zero-nicotine electronic atomizers, and zero-nicotine products will not have the problem of nicotine addiction. At present, the zero-nicotine atomizer products used in the device are mainly rich in flavor and cool, but because they do not contain nicotine, the existing zero-nicotine atomizer preparations do not have the throat hit and head feeling brought by nicotine, and the product satisfaction is weak, which cannot relieve consumers' addiction physiologically.

Summary of the invention

The purpose of the present application is to overcome the defects of the prior art zero-nicotine aerosol preparations that do not have the throat hit and head feeling brought by nicotine, have weak product satisfaction, and cannot relieve consumers' physiological addiction, and further provide a nicotine replacement liquid preparation and its preparation method and application.

In order to achieve the above objectives, this application adopts the following technical solutions:

The present application provides a nicotine replacement liquid preparation, wherein the raw material components of the nicotine replacement liquid preparation include a nicotine throat hit simulation additive, a nicotine head feeling simulation additive and an atomization solvent;

The nicotine throat hit simulating additive is selected from at least one of piperine and 6-methyl nicotine;

The nicotine head-feeling simulating additive is selected from at least one of cytisine, magnolol, and 6-methylnicotine.

Optionally, the total mass content of the nicotine throat hit simulating additive and the nicotine head simulating additive in the nicotine replacement liquid preparation is 2.1-61 mg/g.

Optionally, the mass ratio of the nicotine throat hit simulating additive to the nicotine head feeling simulating additive is (0.1-11):(2-50).

Optionally, the raw material components of the nicotine replacement liquid preparation include 6-methyl nicotine and an atomizing solvent.

Optionally, the mass ratio of the 6-methylnicotine to the atomizing solvent is (0.3-5):(40-95).

Optionally, the raw material components of the nicotine replacement liquid preparation include a nicotine throat hit simulating additive, a nicotine head simulating additive and an atomizing solvent;

The nicotine throat hit simulating additive is selected from at least one of piperine and 6-methyl nicotine;

The nicotine head feeling simulating additive is selected from at least one of cytisine and magnolol.

Optionally, when the nicotine throat hit simulating additive is piperine, the nicotine head simulating additive is cytisine and/or magnolol;

Alternatively, when the nicotine throat hit simulating additive is 6-methyl nicotine, the nicotine head simulating additive is cytisine and/or magnolol.

Optionally, when the nicotine throat hit simulating additive is piperine, the nicotine head feeling simulating additive is cytisine and magnolol, and the mass ratio of cytisine and magnolol is (5-40):(5-30);

Alternatively, when the nicotine throat hit simulating additive is 6-methyl nicotine, the nicotine head simulating additive is cytisine and magnolol, and the mass ratio of cytisine and magnolol is (1-25):(1-5).

Optionally, the mass ratio of the total mass of the nicotine throat hit simulation additive and the nicotine head feeling simulation additive to the atomization solvent is (0.3-5):(40-95).

Optionally, the atomizing solvent includes at least one of propylene glycol and glycerol.

Optionally, the atomizing solvent is propylene glycol and glycerol;

The mass ratio of propylene glycol to glycerol is (1-50):(1-50).

Optionally, the mass content of the nicotine throat hit simulating additive in the nicotine replacement liquid preparation is 0.1-11 mg/g, and the mass content of the nicotine head simulating additive is 2-50 mg/g;

Optionally, the raw material components of the nicotine replacement liquid preparation further include an organic acid.

Optionally, the organic acid includes at least one of C3-C8 organic carboxylic acids;

Optionally, the organic acid includes at least one of C3-C8 monobasic organic carboxylic acid, C3-C8 dibasic organic carboxylic acid, and C3-C8 tribasic organic carboxylic acid.

Optionally, the organic acid includes at least one of salicylic acid, citric acid, malic acid, benzoic acid, levulinic acid, tartaric acid, and succinic acid;

Optionally, the organic acid is benzoic acid.

Optionally, the organic acid is calculated based on the carboxyl group, and the molar ratio of the organic acid to the molar ratio of 6-methylnicotine is 1:(0.98-1.5);

Optionally, the organic acid is calculated based on the carboxyl group, and the molar ratio of the organic acid to the molar ratio of 6-methylnicotine is 1:1.

Optionally, the raw material components of the nicotine replacement liquid preparation further include flavors.

Optionally, the flavor includes at least one of tobacco flavor, fruit flavor, and mint flavor;

Optionally, the fruit flavor includes at least one of mango flavor, blueberry flavor, and grape flavor.

Optionally, the mass ratio of the total mass of the nicotine throat hit simulation additive and the nicotine head feeling simulation additive to the flavor is (0.3-5):(20-45).

The nicotine replacement liquid preparation described in the present application is used to enhance satisfaction, and further, to enhance the satisfaction of consumers.

The present application provides a method for preparing the nicotine replacement liquid preparation as claimed in claim 1, comprising the following steps:

The nicotine throat hit simulating additive, the nicotine head feeling simulating additive and the atomizing solvent are mixed, and then heated and stirred to obtain the atomizing solvent.

Optionally, the method for preparing the nicotine replacement liquid preparation further comprises the step of adding flavors.

Optionally, the method for preparing the nicotine replacement liquid preparation further comprises the step of adding an organic acid.

The present application does not specifically limit the stirring method. Optionally, the stirring method is selected from mechanical stirring, mechanical oscillation or ultrasonic oscillation.

The present application provides a nicotine replacement liquid preparation as described above or a nicotine replacement liquid preparation as described above Application of nicotine replacement liquid preparations in atomizer devices.

Optionally, the atomization device is an electronic atomization device.

Beneficial effects of this application:

The nicotine replacement liquid preparation provided by the present application comprises raw material components including a nicotine throat hit simulation additive, a nicotine head feeling simulation additive and an atomization solvent; the nicotine throat hit simulation additive is selected from at least one of piperine and 6-methylnicotine; the nicotine head feeling simulation additive is selected from at least one of cytisine, magnolol and 6-methylnicotine. The nicotine head-rush simulating additive (at least one of cytisine, magnolol, and 6-methylnicotine) of the present application can make the brain produce a head-rush effect similar to that of nicotine, and can partially replace the activation effect of nicotine. The nicotine throat hit simulating additive (at least one of piperine and 6-methylnicotine) can cause pain, irritation, numbness, itching and other sensations in the human throat, forming a throat hit sensation, wherein 6-methylnicotine has certain effects similar to the head-rush and throat hit of nicotine. Therefore, the nicotine replacement liquid preparation formed by compounding the specific nicotine throat hit simulating additive and the nicotine head-rush simulating additive with the atomization solvent in a specific ratio synergistically simulates the head-rush and throat hit caused by nicotine, improves the head-rush and throat hit of the zero-nicotine atomization preparation, and enhances the satisfaction of the user, thereby achieving the purpose of physiological addiction relief. At the same time, its toxicity and addictiveness are much lower than nicotine, which can reduce health damage.

BRIEF DESCRIPTION OF THE DRAWINGS

In order to more clearly illustrate the specific implementation methods of the present application or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

FIG1 is a graph of average normalized heart rates of Example 1, Example 2, Example 11, and Comparative Example 1 of the present application;

Figure 2 is a normalized heart rate diagram of Example 1, Example 2, Example 11, and Comparative Example 1 of the present application.

DETAILED DESCRIPTION

The following examples are provided for a better understanding of the present application, but are not limited to the best implementation mode described, and do not limit the content and protection scope of the present application. Any product identical or similar to the present application obtained by anyone under the inspiration of the present application or by combining the features of the present application with other prior arts shall fall within the protection scope of the present application.

If no specific experimental steps or conditions are specified in the examples, the conventional experimental steps described in the literature in the field were used. The reagents or instruments used without indicating the manufacturer are all conventional reagents that can be purchased from the market.

The core ingredient in nicotine liquid preparations is nicotine. When the power source heats the atomizer, the nicotine in the nicotine liquid preparation will be atomized into an aerosol and then inhaled by the human body. Part of the aerosol is transmitted to the throat, stimulating the throat to cause a throat hit, and the other part of the aerosol will enter the lungs to participate in the pulmonary venous circulation, and then enter the arterial circulation, quickly transmitting nicotine to the brain, combining with the acetylcholine receptors in the brain, and promoting the brain to release neurotransmitters (dopamine). Dopamine release is a pleasant experience that will enhance the brain's reward function, produce a sense of high, and make smokers feel satisfied, but nicotine is highly toxic and addictive, and long-term inhalation will affect human health. Satisfaction is a comprehensive evaluation of the feeling of high and throat hit. The appropriate throat hit helps to improve the overall satisfaction, but if the throat hit is too strong, it will cause excessive suction irritation and physiological discomfort, which will reduce satisfaction. At present, in order to prevent the abuse of nicotine and protect the health and safety of the public, countries have strictly regulated nicotine in e-cigarette products, prompting many countries to promote zero-nicotine products to avoid nicotine addiction. Zero-nicotine atomized preparations are mainly rich in flavor and cool, but because they do not contain nicotine, the existing zero-nicotine atomized preparations do not have the throat hit and head feeling brought by nicotine, and the product satisfaction is weak, which cannot relieve consumers' physiological addiction.

Cytisine is a natural bioactive compound that is mainly isolated from leguminous plants (especially the seeds of honeysuckle) and is used as an auxiliary tool for clinical management of smoking cessation. Cytisine's main target is neuronal nicotinic acetylcholine receptors (nAChRs). Binding to this receptor can produce neurotransmitters such as dopamine, and the onset of action is similar to that of nicotine.

Magnolia officinalis is the main active ingredient in Magnolia officinalis extract. Magnolia officinalis is a traditional Chinese medicine with many pharmacological activities. In recent years, the research on magnolia officinalis has been continuously deepened at home and abroad. Studies have found that magnolia officinalis has a wide range of pharmacological effects, such as anti-depression, regulation of monoamine neurotransmitter effects, anti-inflammatory, and neuroprotection. In addition, magnolia officinalis can increase the levels of 5-hydroxytryptamine and dopamine in the frontal cortex of mice.

6-methylnicotine (CAS: 13270-56-9) is a synthetic organic compound and a nicotine analog. It has a throat hit very similar to nicotine. The inventors found that the throat hit of 6-methylnicotine is very obvious in the subjective smoking experience. The affinity of nicotine substitutes to nicotinic acetylcholine receptors (nAChR) is related to the lipophilicity of the 6-substituent. Related studies further show that as the size of the substituent increases, the affinity decreases. The affinity of nicotine analogs is determined by the lipophilicity of the 6-substituent and is also related to the size of the substituent. Among them, the 6-substituent of 6-methylnicotine has the smallest volume, strong lipophilicity, and strong affinity with nAChR receptors. Therefore, 6-methylnicotine can produce a similar feeling of being high as nicotine.

Piperine is an alkaloid that is responsible for the spicy taste of pepper and is also the most important biologically active ingredient. As a regulator of human transient receptor potential (TRP) channels, piperine can activate TRP channels, which can cause pain, irritation, numbness and itching in the throat, forming a throat hit similar to nicotine. In addition, science has found that piperine can also inhibit enzymes that play an important role in drug metabolism. By inhibiting drug metabolism, piperine may increase the bioavailability of many compounds, thereby increasing the biological activity of other alkaloids on the human body and helping to enhance the feeling of being high.

The inventor unexpectedly discovered that piperine and 6-methylnicotine can be used as additives to simulate the throat hit of nicotine, and cytisine, magnolol and 6-methylnicotine can be used as additives to simulate the head feeling of nicotine. By matching different combinations of the additives to simulate the throat hit of nicotine and the additives to simulate the head feeling of nicotine, the throat hit and the head feeling brought by nicotine can be simulated in a synergistic manner, thereby improving the throat hit and the head feeling of zero nicotine products and producing a high sense of satisfaction.

The present application provides a nicotine replacement liquid preparation, wherein the raw material components of the nicotine replacement liquid preparation include a nicotine throat hit simulation additive, a nicotine head feeling simulation additive and an atomization solvent; the nicotine throat hit simulation additive is selected from at least one of piperine and 6-methylnicotine; the nicotine head feeling simulation additive is selected from at least one of cytisine, magnolol and 6-methylnicotine. The inventors have found that nicotine head-rush simulating additives (at least one of cytisine, magnolol, and 6-methylnicotine) can make the brain produce a head-rush effect similar to that of nicotine, and can partially replace the activation effect of nicotine. Nicotine throat hit simulating additives (at least one of piperine and 6-methylnicotine) can cause pain, stimulation, numbness, itching and other sensations in the human throat, forming a throat hit sensation, and 6-methylnicotine also has certain head-rush and throat hit effects similar to nicotine. Therefore, a nicotine replacement liquid preparation formed by compounding a specific nicotine throat hit simulating additive and a nicotine head-rush simulating additive with an atomization solvent in a specific ratio synergistically simulates the head-rush and throat hit brought by nicotine, improves the head-rush and throat hit of the zero-nicotine atomization preparation, and enhances the user's satisfaction, thereby achieving the purpose of physiological addiction relief. At the same time, its toxicity and addictiveness are much lower than nicotine, which can reduce health damage.

In some optional embodiments, the total mass content of the nicotine throat hit simulation additive and the nicotine head feeling simulation additive in the nicotine replacement liquid preparation is 2.1-61 mg/g. For example, the total mass content of the nicotine throat hit simulation additive and the nicotine head feeling simulation additive in the nicotine replacement liquid preparation can be selected to be 2.1 mg/g, 2.5 mg/g, 2.6 mg/g, 3 mg/g, 3.5 mg/g, 4 mg/g, 4.5 mg/g, 5 mg/g, 5.6 mg/g, 6 mg/g, 7 mg/g, 8 mg/g, 9 mg/g, 10 mg/g, 11 mg/g, 12 mg/g, 13 mg/g, 14 mg/g, 15 mg/g, 16 mg/g, 17 mg/g, 18 mg/g, 19 mg/g, 20 mg/g, 22 mg/g, 23 mg/g, 24 mg/g g/g, 25mg/g, 26mg/g, 27mg/g, 28mg/g, 29mg/g, 30mg/g, 31mg/g, 32mg/g, 33mg/g, 34mg/g, 35mg/g, 36mg/g, 37mg/g, 38mg/g, 39mg/g, 40mg/g, 4 1mg/g, 42mg/g, 43mg/g, 44mg/g, 45mg/g, 46mg/g, 47mg/g, 48mg/g, 49mg/g, 50mg/g, 51mg/g, 52mg/g, 53mg/g, 54mg/g, 55mg/g, 56mg/g, 57mg/g, 58mg/g, 59mg/g, 60mg/g, 61mg/g.

In some optional embodiments, the mass ratio of the nicotine throat hit simulation additive to the nicotine head feeling simulation additive is (0.1-11):(2-50); for example, the mass ratio of the nicotine throat hit simulation additive to the nicotine head feeling simulation additive can be selected as: 0.1:2, 0.1:3, 0.1:5, 0.1:9, 0.1:10, 0.1:15, 0.1:19, 0.1:20, 0.1:25, 0.1:26, 0.1:30, 0.1:35, 0.1:37, 0.1:40, 0.1:45, 0.1:50, 0.5:2, 0.5:3, 0.5:5, 0.5:9 , 0.5:10, 0.5:15, 0.5:19, 0.5:20, 0.5:25, 0.5:26, 0.5:30, 0.5:35, 0.5:37, 0.5:40, 0.5:45, 0.5:50, 1:2, 1:3, 1:5, 1:9, 1:10, 1:15, 1:19, 1:20, 1:25, 1:26, 1:30, 1:35, 1:37, 1:40, 1:45, 1:50, 3:2, 3:3, 3:5, 3:9, 3:10, 3:15, 3:19, 3:20, 3:25, 3:26, 3:30, 3:35, 3:37, 3:40, 3 :45, 3:50, 5:2, 5:3, 5:5, 5:9, 5:10, 5:15, 5:19, 5:20, 5:25, 5:26, 5:30, 5:35, 5:37, 5:40, 5:45, 5:50, 7:2, 7:3, 7:5, 7:9, 7:10, 7:15, 7:19, 7:20, 7:25, 7:26, 7:30, 7:35, 7:37, 7:40, 7:45, 7:50, 10:2, 10:3, 10:5, 10:9, 10:10, 10:15, 10:19, 10:20, 10:25, 10:26, 10:30, 10:3 The inventors found that by controlling the mass ratio of the nicotine throat hit simulating additive and the nicotine head simulating additive within the range of (0.1-11):(2-50), under their synergistic effect, the user's satisfaction is improved, and the satisfaction can reach or even exceed that of the commercial product with benzoic acid as the organic acid and a nicotine content of 10 mg/g.

The raw material components of the nicotine replacement liquid preparation include 6-methyl nicotine and an atomizing solvent. The inventors have found that 6-methyl nicotine has both a heady feeling and a throat hit effect similar to nicotine, which can greatly improve the user's satisfaction and is even better than nicotine. At the same time, the toxicity and addictiveness are much lower than nicotine, which can reduce damage to human health.

In some optional embodiments, the mass ratio of 6-methyl nicotine to the atomizing solvent is (0.3-5): (40-95). For example, the mass ratio of 6-methyl nicotine to the atomizing solvent can be 0.3:40, 0.3:45, 0.3:47, 0.3:50, 0.3:51, 0.3:55, 0.3:60, 0.3:65, 0.3:70, 0.3:74, 0.3:80, 0.3:85, 0.3:90, 0.3:95, 0.5:40, 0.5:45, 0.5:50, 0.5:51, 0.5:55, 0.5:60, 0.5:65, 0.5:70, 0.5:74, 0.5:80, 0.5:95. 85, 0.5:90, 0.5:95, 1:40, 1:45, 1:47, 1:50, 1:51, 1:55, 1:60, 1:65, 1:70, 1:74, 1:80, 1:85, 1:90, 1:95, 1.5:40, 1.5:45, 1.5:47, 1.5:50, 1.5:51, 1.5:55, 1.5:60, 1.5:65, 1.5:70, 1.5:74, 1.5:80, 1.5:85, 1.5:90, 1.5:95, 2:40, 2:45, 2:47, 2: 50, 2:51, 2:55, 2:60, 2:65, 2:70, 2:74, 2:80, 2:85, 2:90, 2:95, 3:40, 3:45, 3:47, 3:50, 3:51, 3:55, 3:60, 3:65, 3:70, 3:74, 3:80, 3:85, 3:90, 3:95, 4:40, 4:4 5, 4:47, 4:50, 4:51, 4:55, 4:60, 4:65, 4:70, 4:74, 4:80, 4:85, 4:90, 4:95, 5:40, 5:45, 5:47, 5:50, 5:51, 5:55, 5:60, 5:65, 5:70, 5:74, 5:80, 5:85, 5:90, 5:95.

In some optional embodiments, the raw material components of the nicotine replacement liquid preparation include a nicotine throat hit simulation additive, a nicotine head feeling simulation additive and an atomization solvent; the nicotine throat hit simulation additive is selected from at least one of piperine and 6-methylnicotine; the nicotine head feeling simulation additive is selected from at least one of cytisine and magnolol.

In some optional embodiments, the nicotine throat hit simulation additive is piperine, and the nicotine head feeling simulation additive is cytisine. In some optional embodiments, the nicotine throat hit simulation additive is piperine, and the nicotine head feeling simulation additive is magnolol. In other optional embodiments, the nicotine throat hit simulation additive is piperine, and the nicotine head feeling simulation additive is cytisine and magnolol. The mass ratio of cytisine and magnolol is (5-40): (5-30). For example, the mass ratio of cytisine and magnolol can be selected as 5:5, 5:6, 5:8, 10, 5:11, 5:13, 5:15, 5:17, 5:19, 5:20, 5:21, 5:23, 5:25, 5:26, 5:27, 5:28, 5:29, 5:30, 5:31, 5:32, 5:33, 5:34, 5:35, 5:36, 5:37, 5:38, 5:39, 5:40, 5:41, 5:42, 5:43, 5:44, 5:45, 5:46, 5:47, 5:48, 5:49, 5:50, 5:51, 5:52, 5:53, 5:54, 5:55, 5:56, 5:57, 5:58, 5:59, 5:60, 5:61, 5:62, 5:63, 5:64, 5:65, 5:66, 5:67, 5:68, 5:69, 5:70, 5:71, 5:72, 5: :28, 5:29, 5:30, 7:5, 7:6, 7:8, 10, 7:11, 7:13, 7:15, 7:17, 7:19, 7:20, 7:21, 7:23, 7:25, 7:26, 7:28, 7:29, 7:30, 10:5, 10:6, 10:8, 10, 10:11, 10:13, 10: 15, 10:17, 10:19, 10:20, 10:21, 10:23, 10:25, 10:26, 10:28, 10:29, 10:30, 15:5, 15:6, 15:8, 10, 15:11, 15:13, 15:15, 15:17, 15:19, 15:20, 15:21, 15:23 , 15:25, 15:26, 15:28, 15:29, 15:30, 20:5, 20:6, 20:8, 10, 20:11, 20:13, 20:15, 20:17, 20:19, 20:20, 20:21, 20:23, 20:25, 20:26, 20:28, 20:29, 20:30, 25:5, 25:6, 25:8, 10, 25:11, 25:13, 25:15, 25:17, 25:19, 25:20, 25:21, 25:23, 25:25, 25:26, 25:28, 25:29, 25:30, 30:5, 30:6, 30:8, 10, 30:11, 30:13, 30 :15, 30:17, 30:19, 30:20, 30:21, 30:23, 30:25, 30:26, 30:28, 30:29, 30:30, 35:5, 35:6, 35:8, 10, 35:11, 35:13, 35:15, 35:17, 35:19, 35:20, 35:21, 35:2 3, 35:25, 35:26, 35:28, 35:29, 35:30, 40:5, 40:6, 40:8, 10, 40:11, 40:13, 40:15, 40:17, 40:19, 40:20, 40:21, 40:23, 40:25, 40:26, 40:28, 40:29, 40:30. The combination of piperine, cytisine and magnolol significantly improves the user's satisfaction compared to the combination of cytisine and piperine or the use of cytisine alone. Magnolia officinalis and piperine are combined.

In some optional embodiments, the nicotine throat hit simulation additive is 6-methylnicotine, and the nicotine head feeling simulation additive is cytisine. In some optional embodiments, the nicotine throat hit simulation additive is 6-methylnicotine, and the nicotine head feeling simulation additive is magnolol. In other optional embodiments, the nicotine throat hit simulation additive is 6-methylnicotine, and the nicotine head feeling simulation additive is cytisine and magnolol. The mass ratio of cytisine and magnolol is (1-25): (1-5). For example, the mass ratio of cytisine and magnolol can be selected from 1:1, 2:1, 5:1, 7:1, 9:1, 10:1, 12:1, 13:1, 15:1, 18:1, 19:1, 20:1, 21:1, 24:1, 25:1, 1:2, 2:2, 5:2, 7:2, 9:2, 10:2, 12:2, 13:2, 15:2, 18:2, 19:2, 20:2, 21:2, 24:2, 25:2, 1:3, 2:3, 5:3, 7:3, 9:3, 10:3, 12:3, 13:3, 15:3, 18:3, 19:3, 20:3, 21:3, 24:3, 25:3, 1: 4, 2:4, 5:4, 7:4, 9:4, 10:4, 12:4, 13:4, 15:4, 18:4, 19:4, 20:4, 21:4, 24:4, 25:4, 1:5, 2:5, 5:5, 7:5, 9:5, 10:5, 12:5, 13:5, 15:5, 18:5, 19:5, 20:5, 21:5, 24:5, 25:5. The combination of 6-methylnicotine, cytisine and magnolol significantly improves the satisfaction of users compared with the combination of cytisine and 6-methylnicotine or magnolol and 6-methylnicotine alone.

In some optional embodiments, the atomizing solvent may be a conventional atomizing solvent in the art, including but not limited to at least one of propylene glycol and glycerol; optionally, the mass ratio of the total mass of the nicotine throat hit simulation additive and the nicotine head feeling simulation additive to the atomizing solvent is (0.3-5):(40-95), for example, the mass ratio of the total mass of the nicotine throat hit simulation additive and the nicotine head feeling simulation additive to the atomizing solvent can be selected to be 0.3:40, 0.3:45, 0.3:47, 0.3:50, 0.3:51, 0.3:5 5. 0.3:60, 0.3:65, 0.3:70, 0.3:74, 0.3:80, 0.3:85, 0.3:90, 0.3:95, 0.5:40, 0.5:45, 47, 0.5:50, 0.5:51, 0.5:55, 0.5:60, 0.5:65, 0.5:70, 0.5:74, 0.5:80, 0.5:85, 0.5:90, 0.5:95, 1:40, 1:45, 1:47, 1:50, 1:51, 1:55, 1:60, 1:65, 1:70, 1: 74, 1:80, 1:85, 1:90, 1:95, 1.5:40, 1.5:45, 1.5:47, 1.5:50, 1.5:51, 1.5:55, 1.5:60, 1.5:65, 1.5:70, 1.5:74, 1.5:80, 1.5:85, 1.5:90, 1.5:95, 2:40, 2:45, 2:47, 2:50, 2:51, 2:55, 2:60, 2:65, 2:70, 2:74, 2:80, 2:85, 2:90, 2:95, 3:40, 3:4 5, 3:47, 3:50, 3:51, 3:55, 3:60, 3:65, 3:70, 3:74, 3:80, 3:85, 3:90, 3:95, 4:40, 4:45, 4:47, 4:50, 4:51, 4:55, 4:60, 4:65, 4:70, 4:74, 4:80, 4:85, 4:90, 4:95, 5:40, 5:45, 5:47, 5:50, 5:51, 5:55, 5:60, 5:65, 5:70, 5:74, 5:80, 5:85, 5:90, 5: 95. Optionally, the atomizing solvent is propylene glycol and glycerol. The mass ratio of propylene glycol to glycerol is (1-50): (1-50). Optionally, the mass ratio of propylene glycol to glycerol ethanol is 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:13, 1:15, 1:20, 1:25, 1:30, 1:35, 1:40, 1:45, 1:50, 2:1, 2:3, 2:5, 2:7, 2:9, 2:1 0, 2:13, 2:15, 2:20, 2:25, 2:30, 2:35, 2:40, 2:45, 2:50, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 12:1, 13:1, 15:1, 18:1, 20:1, 22:1, 25:1, 29:1, 30:1, 32:1, 35:1, 40:1, 43:1, 45:1, 47:1, 50:1. The addition of the atomizing solvent in the present application can better dissolve the raw material components, effectively improve the atomization efficiency of nicotine, and increase satisfaction.

In some optional embodiments, the mass content of the nicotine throat hit simulating additive in the nicotine replacement liquid preparation is 0.1-11 mg/g, and the mass content of the nicotine head simulating additive is 2-50 mg/g. For example, the mass content of A in the nicotine replacement liquid preparation can be selected to be 0.1 mg/g, 0.5 mg/g, 0.7 mg/g, 0.9 mg/g, 1 mg/g, 1.1 mg/g, 1.5 mg/g, 1.7 mg/g, 2 mg/g, 2.3 mg/g, 2.5 mg/g, 2.7 mg/g, 3 mg/g, 3.5 mg/g, 3.7 mg/g, 4 mg/g, 4.5 mg/g, 4.8 The mass content of nicotine head-feeling additives is 2mg/g, 3mg/g, 4mg/g, 5mg/g, 6mg/g, 7mg/g, 8mg/g, 9mg/g, 10mg/g, 11mg/g, and the mass content of nicotine head-feeling additives is 2mg/g, 3mg/g, 4mg/g, 5mg/g, 6mg/g, 7mg/g, 8mg/g, 8mg/g, 9mg/g, 10mg/g, 11mg/g, and the mass content of nicotine head-feeling additives is 2mg/g, 3mg/g, 4mg/g, 5mg/g, 6mg/g, 7mg/g, 8mg/g, 8mg/g, 8mg/g, 9mg/g, 10mg/g, 11mg/g. mg/g, 6mg/g, 7mg/g, 8mg/g, 9mg/g, 10mg/g, 11mg/g, 12mg/g, 13mg/g, 14mg/g, 15mg/g, 16mg/g, 1 7mg/g, 18mg/g, 19mg/g, 20mg/g, 21mg/g, 22mg/g, 23mg/g, 24mg/g, 25mg/g, 26mg/g, 27mg/g, 28m g/g, 29mg/g, 30mg/g, 31mg/g, 32mg/g, 33mg/g, 34mg/g, 35mg/g, 36mg/g, 37mg/g, 38mg/g, 39mg/ g, 40mg/g, 41mg/g, 42mg/g, 43mg/g, 44mg/g, 45mg/g, 46mg/g, 47mg/g, 48mg/g, 49mg/g, 50mg/g.

In some optional embodiments, the raw material components of the nicotine replacement liquid preparation also include an organic acid. Optionally, the organic acid includes at least one of C3-C8 organic carboxylic acids; further optionally, the organic acid includes at least one of C3-C8 monobasic organic carboxylic acids, C3-C8 dibasic organic carboxylic acids, and C3-C8 tribasic organic carboxylic acids. Further optionally, the organic acid includes at least one of salicylic acid, citric acid, malic acid, benzoic acid, levulinic acid, tartaric acid, and succinic acid; further optionally, the organic acid is benzoic acid. The present application can further ensure the user's satisfaction by further adding a specific organic acid to the raw material components to form a nicotine salt.

In some optional embodiments, the molar amount of the organic acid is calculated based on the carboxyl group, and the molar amount ratio of the organic acid to 6-methyl nicotine is 1:(0.98-1.5); for example, the molar amount of the organic acid is calculated based on the carboxyl group, and the molar amount ratio of the organic acid to 6-methyl nicotine is 1:0.98, 1:0.99, 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5. After 6-methyl nicotine, the inventors further found that organic acids and their added amounts would affect satisfaction. Changing the molar ratio of organic acid to 6-methyl nicotine can change the acid-base environment of the throat and adjust the throat hit during the aerosol entering the lungs. Optionally, the organic acid is calculated based on the carboxyl group, and the molar ratio of the organic acid to the molar ratio of 6-methyl nicotine is 1:1.

In some optional embodiments, the raw material components of the nicotine replacement liquid preparation also include flavors. The flavors may be conventional existing flavor materials in the art, which may be obtained commercially or prepared by conventional components by conventional methods, for example, monomeric flavor raw materials or a variety of extracts may be selected. Including but not limited to tobacco flavors, fruit flavors, and mint flavors. Further, the fruit flavors include at least one of mango flavors, blueberry flavors, and grape flavors; optionally, the mass ratio of the total mass of the nicotine throat hit simulation additive and the nicotine head feeling simulation additive to the mass ratio of the flavor is (0.3-5): (20-45), for example, the mass ratio of the total mass of the nicotine throat hit simulation additive and the nicotine head feeling simulation additive to the mass ratio of the flavor may be 0.3:20, 0.3:25, 0.3:30, 0.3:35, 0.3:40, 0.3:45, 0.5:20, 0.5:25, 0.5:30, 0.5:35 , 0.5:40, 0.5:45, 1:20, 1:25, 1:30, 1:35, 1:40, 1:45, 1.5:20, 1.5:25, 1.5:30, 1.5:35, 1.5:40, 1.5:45, 2:20, 2:25, 2:30, 2:35, 2:40, 2:45, 3:20, 3:25, 3:30, 3:35, 3:40, 3:45, 4:20, 4:25, 4:30, 4:35, 4:40, 4:45, 5:20, 5:25, 5:30, 5:35, 5:40, 5:45

The present application also provides a method for preparing the above-mentioned nicotine replacement liquid preparation, comprising the following steps: mixing a nicotine throat hit simulating additive, a nicotine head feeling simulating additive and an atomizing solvent, and then heating and stirring the mixture to obtain a nicotine replacement liquid preparation.

In some optional embodiments, the method for preparing the nicotine replacement liquid preparation further comprises the step of adding flavors.

In some optional embodiments, the method for preparing the nicotine replacement liquid preparation further comprises the step of adding an organic acid.

The present application does not make specific restrictions on the heating and stirring temperature and time, as long as the raw materials can be dissolved, and optionally, the dissolution temperature is not higher than 100°C. Optionally, the heating and stirring temperature is 40-65°C, and the heating and stirring time is 20-30min. The present application does not make specific restrictions on the mixing method and the order of mixing. Optionally, in the present application, all the raw materials can be mixed and then heated and dissolved, or some of the raw materials can be mixed and dissolved first, and then the remaining raw materials can be mixed and dissolved.

In some optional embodiments, the method for preparing the nicotine replacement liquid preparation comprises the following steps: mixing a nicotine head-feeling simulating additive, a nicotine throat-hit simulating additive, an organic acid and a portion of an atomizing solvent; Heat at 40-65° C. for 20-30 minutes to dissolve and mix evenly, cool to 10-35° C., add flavor and stir for 5-40 minutes to mix evenly, to obtain the nicotine replacement liquid preparation.

In some optional embodiments, the method for preparing the nicotine replacement liquid preparation comprises the following steps: mixing a nicotine head-feeling simulation additive, a nicotine throat-hit simulation additive, an organic acid and a portion of an atomizing solvent, heating at 40-65° C. for 20-30 minutes to dissolve and mix uniformly, cooling to room temperature, adding flavor and stirring for 5-40 minutes to mix uniformly, to obtain the nicotine replacement liquid preparation.

The present application also provides a use of the above-mentioned nicotine replacement liquid preparation or the nicotine replacement liquid preparation prepared by the above-mentioned preparation method in an atomization device. Optionally, the atomization device is an electronic atomization device.

Example 1

This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

0.6 g 6-methylnicotine, 1 g magnolol, 0.42 g benzoic acid, 12.98 g propylene glycol and 40 g glycerol were mixed, stirred at 60° C. for 20 min to mix evenly, cooled to room temperature, and 45 g blueberry flavor was added and stirred for 20 min to mix evenly to obtain the nicotine replacement liquid preparation.

Example 2

This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

0.6 g 6-methylnicotine, 1 g cytisine, 0.42 g benzoic acid, 12.98 g propylene glycol and 40 g propylene glycol were mixed, stirred at 60° C. for 20 min to mix evenly, cooled to room temperature, and 45 g blueberry flavor was added and stirred for 20 min to mix evenly to obtain the nicotine replacement liquid preparation.

Example 3

This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

0.01 g of piperine, 4.5 g of cytisine, 10.49 g of propylene glycol and 40 g of glycerol were mixed, stirred at 60° C. for 20 min to make the mixture uniformly mixed, and after cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 min to make the mixture uniformly mixed, thereby obtaining the nicotine replacement liquid preparation.

Example 4

This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

0.01 g of piperine, 4.5 g of magnolol, 10.49 g of propylene glycol and 40 g of glycerol were mixed, stirred at 60° C. for 20 min to make the mixture uniformly mixed, and after cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 min to make the mixture uniformly mixed, thereby obtaining the nicotine replacement liquid preparation.

Example 5

This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

3 g of cytisine, 1.5 g of magnolol, 0.01 g of piperine, 10.49 g of propylene glycol and 40 g of glycerol were mixed, stirred at 60° C. for 20 min to make the mixture uniformly mixed, and after cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 min to make the mixture uniformly mixed, thereby obtaining the nicotine replacement liquid preparation.

Example 6

This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

3.0 g of cytisine, 1.5 g of magnolol, 0.05 g of piperine, 10.45 g of propylene glycol and 40 g of glycerol were mixed, stirred at 60° C. for 20 min to make the mixture uniformly mixed, cooled to room temperature, and then 45 g of blueberry flavor was added and stirred for 20 min to make the mixture uniformly mixed, thereby obtaining the nicotine replacement liquid preparation.

Example 7

This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

3.0 g of cytisine, 1.5 g of magnolol, 0.1 g of piperine, 10.4 g of propylene glycol and 40 g of glycerol were mixed, stirred at 60° C. for 20 min to make the mixture uniformly mixed, cooled to room temperature, and then 45 g of blueberry flavor was added and stirred for 20 min to make the mixture uniformly mixed, thereby obtaining the nicotine replacement liquid preparation.

Example 8

This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

0.3 g 6-methylnicotine, 0.21 g benzoic acid, 14.49 g propylene glycol and 40 g propylene glycol were mixed, stirred at 60° C. for 20 min to make the mixture evenly mixed, cooled to room temperature, and 45 g blueberry flavor was added and stirred for 20 min to make the mixture evenly mixed to obtain the nicotine replacement liquid preparation.

Example 9

This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

0.6 g 6-methylnicotine, 0.42 g benzoic acid, 13.98 g propylene glycol and 40 g propylene glycol were mixed, stirred at 60° C. for 20 min to make the mixture evenly mixed, cooled to room temperature, and 45 g blueberry flavor was added and stirred for 20 min to make the mixture evenly mixed to obtain the nicotine replacement liquid preparation.

Example 10

This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

1.0 g 6-methylnicotine, 0.69 g benzoic acid, 13.31 g propylene glycol and 40 g propylene glycol were mixed, stirred at 60° C. for 20 min to make the mixture evenly mixed, cooled to room temperature, and 45 g blueberry flavor was added and stirred for 20 min to make the mixture evenly mixed to obtain the nicotine replacement liquid preparation.

Embodiment 11

This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

0.6 g 6-methylnicotine, 0.5 g cytisine, 0.5 g magnolol, 0.42 g benzoic acid, 12.98 g propylene glycol and 40 g glycerol were mixed, stirred at 60° C. for 20 min to mix evenly, cooled to room temperature, and 45 g blueberry flavor was added and stirred for 20 min to mix evenly to obtain the nicotine replacement liquid preparation.

Example 12

This embodiment provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

0.6 g 6-methylnicotine, 3.0 g cytisine, 1.5 g magnolol, 0.42 g benzoic acid, 9.48 g propylene glycol and 40 g glycerol were mixed, stirred at 60° C. for 20 min to mix evenly, cooled to room temperature, and 45 g blueberry flavor was added and stirred for 20 min to mix evenly to obtain the nicotine replacement liquid preparation.

Example 13

1.0 g 6-methylnicotine, 3.0 g cytisine, 1.5 g magnolol, 0.69 g benzoic acid, 8.81 g propylene glycol and 40 g glycerol were mixed, stirred at 60° C. for 20 min to mix evenly, cooled to room temperature, and 45 g blueberry flavor was added and stirred for 20 min to mix evenly to obtain the nicotine replacement liquid preparation.

Comparative Example 1

This comparative example provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

15 g of propylene glycol and 40 g of glycerol were mixed, stirred at 60° C. for 20 min to make the mixture uniformly mixed, and after cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 min to make the mixture uniformly mixed, thereby obtaining the nicotine replacement liquid preparation.

Comparative Example 2

This comparative example provides a method for preparing a nicotine liquid preparation, comprising the following steps:

1 g of nicotine, 0.75 g of benzoic acid, 13.25 g of propylene glycol and 40 g of glycerol were mixed, stirred at 60° C. for 20 min to make the mixture uniformly mixed, and after cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 min to make the mixture uniformly mixed, thereby obtaining the nicotine liquid preparation.

Comparative Example 3

This comparative example provides a method for preparing a nicotine liquid preparation, comprising the following steps:

2 g of nicotine, 1.5 g of benzoic acid, 11.5 g of propylene glycol and 40 g of glycerol were mixed, stirred at 60° C. for 20 min to make the mixture uniformly mixed, and after cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 min to make the mixture uniformly mixed, thereby obtaining the nicotine liquid preparation.

Comparative Example 4

This comparative example provides a method for preparing a nicotine liquid preparation, comprising the following steps:

3 g of nicotine, 2.26 g of benzoic acid, 9.74 g of propylene glycol and 40 g of glycerol were mixed, stirred at 60° C. for 20 min to make the mixture uniformly mixed, and after cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 min to make the mixture uniformly mixed to obtain the Nicotine liquid preparations.

Comparative Example 5

This comparative example provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

3.0 g of cytisine, 12 g of propylene glycol and 40 g of glycerol were mixed, stirred at 60° C. for 20 min to make the mixture uniformly mixed, and after cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 min to make the mixture uniformly mixed, thereby obtaining the nicotine replacement liquid preparation.

Comparative Example 6

This comparative example provides a method for preparing a nicotine replacement liquid preparation, comprising the following steps:

1.5 g of magnolol, 13.5 g of propylene glycol and 40 g of glycerol were mixed, stirred at 60° C. for 20 min to make the mixture uniformly mixed, and after cooling to room temperature, 45 g of blueberry flavor was added and stirred for 20 min to make the mixture uniformly mixed, thereby obtaining the nicotine replacement liquid preparation.

Test Case

This application uses a subjective smoking method to score various smoking indicators of the liquid preparations of Examples 1-13 and Comparative Examples 1-6. The smoking team consists of 15 people, all of whom have more than 3 years of experience in smoking traditional cigarettes or electronic cigarettes, and have undergone nicotine withdrawal 10 hours before smoking.

Each smoker is given a smoke taste evaluation form, and the nicotine replacement liquid preparations or nicotine liquid preparations of different embodiments and comparative examples are smoked by dark evaluation. The smoking method is as follows: the smoker performs nicotine withdrawal for 10 hours the night before smoking, and performs a smoking test at 9 am on the day of smoking. A total of 10 puffs of smoke are smoked using a RELX5 generation electronic cigarette rod (with different embodiments and comparative examples) (3 seconds per puff, 27 seconds between each puff), and after smoking, the smoke is scored and evaluated according to the evaluation indicators in Table 1. After smoking a sample of smoke oil, quit smoking for 2 hours, and then perform a smoking test on the next sample of smoke oil. The results of the smoking test are shown in Table 2 (the scoring value is the average score).

Table 1 Evaluation indicators

Table 2 Product absorption scoring data

The liquid preparations prepared in Example 1, Example 2, Example 11 and Comparative Example 1 (hereinafter referred to as samples) were tested for heart rate during the smoking process. The test method is: the smoking personnel perform nicotine withdrawal the night before the smoking test, and perform a heart rate test during the smoking process at 9 am on the day of smoking. Before smoking, wear the heart rate test instrument (the heart rate test instrument is Lepu Xinanbao ER1), and monitor the real-time changes of the heart rate throughout the smoking process. After the heart rate instrument is worn and debugged, a 2-minute baseline heart rate test is performed. After the heart rate stabilizes, start the heart rate monitoring of the smoking process, use the RELX5 cigarette rod (with samples of different embodiments and comparative examples), and draw a total of 5 puffs of smoke (3s per puff, 27s between adjacent puffs), the whole smoking time is about 2.5min, and the time when each puff of smoke starts is recorded. After the smoking is completed, the heart rate changes are monitored for another 1min, and then the experiment is terminated. After finishing one sample, abstain for 2 hours before testing the heart rate during the next sample. The test results are shown in Figures 1 and 2, where the average normalized heart rate in Figure 1 is the ratio of the average monitored heart rate during the smoking process to the average baseline heart rate, and the normalized heart rate in Figure 2 is the ratio of the real-time monitored heart rate during the smoking process to the average baseline heart rate within the above 2 minutes.

Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.

Claims (24)

A nicotine replacement liquid preparation, characterized in that the raw material components of the nicotine replacement liquid preparation include a nicotine throat hit simulating additive, a nicotine head simulating additive and an atomizing solvent; The nicotine throat hit simulating additive is selected from at least one of piperine and 6-methyl nicotine; The nicotine head-feeling simulating additive is selected from at least one of cytisine, magnolol, and 6-methylnicotine. The nicotine replacement liquid preparation according to claim 1, characterized in that the total mass content of the nicotine throat hit simulation additive and the nicotine head simulation additive in the nicotine replacement liquid preparation is 2.1-61 mg/g. The nicotine replacement liquid preparation according to claim 1 or 2, characterized in that the mass ratio of the nicotine throat hit simulation additive to the nicotine head feeling simulation additive is (0.1-11):(2-50). The nicotine replacement liquid preparation according to any one of claims 1 to 3, characterized in that the raw material components of the nicotine replacement liquid preparation include 6-methyl nicotine and an atomizing solvent. The nicotine replacement liquid preparation according to claim 4, characterized in that the mass ratio of 6-methyl nicotine to the atomizing solvent is (0.3-5): (40-95). The nicotine replacement liquid preparation according to any one of claims 1 to 3, characterized in that the raw material components of the nicotine replacement liquid preparation include a nicotine throat hit simulating additive, a nicotine head simulating additive and an atomizing solvent; The nicotine throat hit simulating additive is selected from at least one of piperine and 6-methyl nicotine; The nicotine head feeling simulating additive is selected from at least one of cytisine and magnolol. The nicotine replacement liquid preparation according to claim 6, characterized in that when the nicotine throat hit simulating additive is piperine, the nicotine head simulating additive is cytisine and/or magnolol; Alternatively, when the nicotine throat hit simulating additive is 6-methyl nicotine, the nicotine head simulating additive is cytisine and/or magnolol. The nicotine replacement liquid preparation according to claim 7, characterized in that when the nicotine throat hit simulating additive is piperine, the nicotine head simulating additive is cytisine and magnolol, and the mass ratio of cytisine and magnolol is (5-40): (5-30); Alternatively, when the nicotine throat hit simulating additive is 6-methyl nicotine, the nicotine head simulating additive is cytisine and magnolol, and the mass ratio of cytisine and magnolol is (1-25):(1-5). The nicotine replacement liquid preparation according to any one of claims 1 to 8, characterized in that the mass ratio of the total mass of the nicotine throat hit simulation additive and the nicotine head simulation additive to the atomization solvent is (0.3-5):(40-95). The nicotine replacement liquid preparation according to any one of claims 1 to 9, characterized in that the atomization solvent comprises at least one of propylene glycol and glycerol. The nicotine replacement liquid preparation according to any one of claims 1 to 10, characterized in that the atomization solvent is propylene glycol and glycerol; The mass ratio of propylene glycol to glycerol is (1-50):(1-50). The nicotine replacement liquid preparation according to any one of claims 1 to 11, characterized in that the mass content of the nicotine throat hit simulation additive in the nicotine replacement liquid preparation is 0.1-11 mg/g, and the mass content of the nicotine head simulation additive is 2-50 mg/g. The nicotine replacement liquid preparation according to any one of claims 1 to 12, characterized in that the raw material components of the nicotine replacement liquid preparation further include an organic acid. The nicotine replacement liquid preparation according to claim 13, characterized in that the organic acid comprises at least one of C3-C8 organic carboxylic acids; Optionally, the organic acid includes at least one of C3-C8 monobasic organic carboxylic acid, C3-C8 dibasic organic carboxylic acid, and C3-C8 tribasic organic carboxylic acid. The nicotine replacement liquid preparation according to claim 13 or 14, characterized in that the organic acid comprises at least one of salicylic acid, citric acid, malic acid, benzoic acid, levulinic acid, tartaric acid, and succinic acid; Optionally, the organic acid is benzoic acid. The nicotine replacement liquid preparation according to any one of claims 13 to 15, characterized in that the molar amount of the organic acid is calculated based on the carboxyl group, and the molar amount ratio of the organic acid to 6-methyl nicotine is 1: (0.98-1.5); Preferably, the molar ratio of the organic acid to the molar ratio of 6-methylnicotine is 1:1, calculated based on the carboxyl group of the organic acid. The nicotine replacement liquid preparation according to any one of claims 1 to 16, characterized in that the raw material components of the nicotine replacement liquid preparation further include flavors. The nicotine replacement liquid preparation according to claim 17, characterized in that the flavor comprises at least one of tobacco flavor, fruit flavor, and mint flavor; Optionally, the fruit flavor includes at least one of mango flavor, blueberry flavor, and grape flavor. The nicotine replacement liquid preparation according to claim 17 or 18, characterized in that the mass ratio of the total mass of the nicotine throat hit simulation additive and the nicotine head simulation additive to the flavor is (0.3-5):(20-45). A method for preparing the nicotine replacement liquid preparation according to any one of claims 1 to 19, characterized in that it comprises the following steps: The nicotine throat hit simulating additive, the nicotine head feeling simulating additive and the atomizing solvent are mixed, and then heated and stirred to obtain the atomizing solvent. The method for preparing a nicotine replacement liquid preparation according to claim 20, further comprising the step of adding flavoring. The method for preparing a nicotine replacement liquid preparation according to claim 20 or 21, further comprising the step of adding an organic acid. Use of the nicotine replacement liquid preparation according to any one of claims 1 to 19 or the nicotine replacement liquid preparation prepared by the preparation method according to any one of claims 20 to 22 in an atomization device. The use according to claim 23 is characterized in that the atomization device is an electronic atomization device.